Grace Therapeutics Business Summary

Grace Therapeutics, Inc. (Nasdaq: GRCE) is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare and orphan diseases, particularly in the neurology and critical care segments. The company operates a pre-revenue business model, currently generating no product sales as it prioritizes the clinical advancement and regulatory approval of its lead asset, GTx-104. Revenue is projected to stem from future commercial launches, licensing agreements, or milestone payments following the anticipated FDA approval of GTx-104, an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage (aSAH) with a PDUFA target date of April 23, 2026. Grace Therapeutics competes with specialty pharmaceutical firms such as Cumberland Pharmaceuticals, Lipocine Inc., and NRx Pharmaceuticals, positioning itself as a high-growth clinical disruptor aiming to replace the cumbersome oral standard of care in acute brain injury settings. The leadership team is led by CEO Prashant Kohli, who brings over 20 years of commercial strategy experience from roles at Cardinal Health and IMS Health. The company’s technical and clinical direction is overseen by Chief Medical Officer Dr. R. Loch Macdonald, a world-renowned neurosurgeon and former Head of Neurosurgery at St. Michael’s Hospital, recognized as a leading expert in brain hemorrhage. Financial operations are managed by Robert J. DelAversano, who serves as the Principal Financial Officer. The company’s strategic foundation is reinforced by board member and Grace co-founder Vimal Kavuru, a seasoned pharmaceutical entrepreneur and founder of Rising Pharma. Notable institutional backing includes significant positions held by AIGH Capital Management and Nantahala Capital Management, reflecting strong investor confidence in the company’s late-stage pipeline and upcoming regulatory catalysts.